Virbac SA (VIRP) Earnings Call Transcript & Summary
September 18, 2026
Earnings Call Speaker Segments
Carole Manducher
executiveGood afternoon, everyone — and good morning to those of you joining from further away. It's a real pleasure to have you with us for these half year results 2026. If you don't know me, my name is Carole Manducher, and I serve as Global Head of Communications at Virbac. Joining me is Taron Hovhannissyan, our Investor Relations Director. And naturally, here in the room today we also have Paul Martingell, our CEO, plus Habib Ramdani, our CFO and Deputy CEO. So I'll hand things over to Paul and Habib, who will walk you through our half year results and the various perspectives we hold. Once they're done, you'll have the chance to ask your questions. Please feel free to go ahead and use the chat or the questions room to begin submitting them now, so that we're ready to fire away once the presentations wrap up. Many thanks. Paul, over to you.
Paul Martingell
executiveThanks, Carole. Good afternoon and good morning, everyone. It's a pleasure as always to be on this call with you, walking you through our half year 2026 results and also tying them back to a few of the strategic updates we gave you early this year. Let me offer a handful of high-level messages myself, and then Habib will dig deeper into the financials later on. The first half performance was very, very solid, and we're very happy with it. As you've seen, growth came in at 7.4%, really powered by our Supercharge platforms — the ones we shared with you in the Growing Together strategy we announced earlier this year. Those platforms are growing double digits. And as you see in the second point, they're also bringing a nice favorable margin mix to the business, with operating profit at 18.8% for the first half, up 50 basis points versus prior year. At the same time, while we delivered that strong and disciplined financial performance, we keep investing strongly for our future growth and sustainable development — significant and strong continuing impact in R&D, in our CapEx investments to make sure we have the capacity for growth, agility and great customer service going forward, and also increasingly in A&P, advertising and promotional spend, given the ongoing shift towards an omnichannel business model and the share of our business that starts to become more direct-to-consumer in nature.
Paul Martingell
executiveI brought up the industrial transformation earlier, and we'll go into a bit more detail on that, but there are 3 or 4 key projects that you're well aware of. Glad to share that with the teams we've put in place and some of the capabilities we've been building — those projects are being managed and executed very well, and all are on track and as planned. In the first half, we as a team have also seen how agile Virbac can be in the face of some quite significant challenges, of course — whether that's the inflationary pressures on oil from the Middle East crisis and, of course, the changing nature of tariff discussions in the U.S. — and we've managed to offset that and keep delivering margin expansion as planned in our Growing Together strategy. Lastly, on another important piece of our strategy: as you know, external growth remains a top priority for Virbac. I'm delighted to say that the integration of the Thyronorm brand, which we acquired at the end of 2025, is absolutely seamlessly on track and, at this stage, is performing even ahead of our initial expectations. So great mobilization from the team. That again gives us the confidence to keep searching for those bolt-on acquisitions, small and medium size.
Paul Martingell
executiveAnd actually, during the first half of this year, we signed 2 smaller deals — though they're still worth mentioning: 2 licensing agreements in innovation areas within specialty segments that fit extremely well with our Supercharge and core platforms. In both instances, we not only hold the initial distribution right for chosen geographies, but we also have an option to fully acquire those brands. All of which is to say that the ongoing responsibility you've always had with Virbac remains. And as you're aware, the strong performance in the first half gives us the confidence to share that we're now aiming at the upper end of our sales growth range for 2026, along with a confirmed EBIT margin of around 17%. Turning to the external perspective, which for us is truly the #1 measure of our performance, you'd have seen externally that other competitors perhaps don't view things quite so favorably; we do see the market remaining robust. Yes, there's a slowdown in companion in the U.S. But as you know, Virbac has a very broad portfolio spanning both companion and farm, and internationally.
Paul Martingell
executiveSo when we look at our reference market, it still appears to be a rather healthy one. Yes, there's a slight slowdown. But more importantly, we keep seeing that the Virbac teams, along with the pipeline and portfolio we have, are able to perform consistently above that market — and again, another free continuous quarters where we've been growing and perhaps even accelerating the gap versus the market, showing that real customer closeness that we enjoy and, I would say, an increasing focus on execution in the market. As you know, earlier this year we did make a change to our executive committee structure, now operating these three regions, really to ensure, again, closeness to our customers and the voice of the customer as part of our leadership team. Europe, of course, still a very, very strong home and center of the Virbac business, still delivering very positive and strong growth. But clearly, the highlights in half 1 came in both the North America region with double-digit growth in the U.S., which, as you know, is an absolute priority for us to really build a significantly stronger position in that market, and it's another strong double-digit growth for the first 6 months of the year following 2 or 3 years before that as well of double-digit growth in the U.S.
Paul Martingell
executiveThen looking at the international region, where we're once again seeing double-digit growth — India in particular is performing very strongly, and Latin America too — that more than compensates for certain headwinds in the Pacific region, where, as I mentioned, we've adjusted some of our commercial organization setup and approach, and we're beginning to pick up more encouraging signals out of that part of the world. But once again, with the strong diversity of our business across segments and countries, plus the agility of our teams, we're delighted to be able to post that 7.4% growth for the first half, though it's well split and well spread across all major geographies. Just a reminder of the strategy we shared earlier this year. And of course, this is year 1 on that journey. So there's plenty for us to do. You can clearly see the very strong positive impact that the focus on those Supercharged platforms is having, both on top line and on gross margin. On the next chart, which I'll come on to, I'll just put a bit more flavor behind what we have in that part of our business. Also shared again today were two nice examples with the Porus One and Vetcare deals that we've shared, in terms of our ability to be a partner of choice when it comes to external collaboration, along with a very active and ongoing BD organization and the omnichannel transformation that we continue to go through.
Paul Martingell
executiveMuch of the team's attention during the first half—and this will keep being the case moving forward—is on truly delivering with excellence, on the commercial side as well as the industrial side, so that we can counter every one of those other difficulties and become even more efficient and effective. There is certainly far more work to be done in that regard, yet the team is already showing genuine passion and making gains in those areas, helped too by what we are investing in data and digital, which gives us far more tools and information to support that decision-making. Moving to the next chart, you'll see once more—as we discussed during the last strategy update—a bit more detail on those supercharged platforms that are delivering such strong performance. Ear is a genuinely good illustration, a surprisingly common and frequent problem for pet parents and for our customers, the vets. Indeed, allergy—and ear is a significant part of that—is an extremely frequent reason pet parents bring their animals to the vet clinic, and it is an area where our portfolio and position keep getting stronger across a number of highly trusted brands like Easotic, Epiotic and increasingly Cortotic, which is a very good innovation posting very strong growth, since it is the first antibiotic-free treatment in that space at a moment when antibiotic resistance is, of course, a key theme for our customers.
Paul Martingell
executiveWhen it comes to mobility, that's a really strong platform for us, and Movoflex is doing very well, since life expectancy keeps rising and pet parents expect more when it comes to quality of life for those animals. Movoflex is performing very well, and more recently URSOLYX in the U.S. — a fantastically executed launch that is also, again, beating expectations. So we keep building our portfolio and our expertise in that space. And on farm animals, responding, of course, to some of the important one health challenges around zoonotic diseases that we've seen, especially across the last couple of years. And of course, with the ongoing need for prevention and quality protein sources, the team remains very well mobilized, and we hold a very strong position there, particularly in injectable trace minerals — an area that is increasingly understood and important for supporting livestock health prevention at key moments for the farmers and customers on those journeys. So we'll keep providing more flavor and color on our Supercharge platforms, but again, growing around 12% in the first half of the year. So very, very solid performance. Finally, I touched on a little bit of that, and you would have seen it in our press releases — two very nice complementary deals that we've been able to sign in the first half of the year, again, showing the agility and the very strong perception of Virbac as a potential partner of choice for companies that are developing such innovations.
Paul Martingell
executiveThere are two distribution licensing deals that, for the geographies outlined here, starting in 2027, will give us distribution of these highly interesting brands and innovation. We see a very strong fit in two areas where Virbac is strong. But even more importantly, in both cases we hold an option, under certain conditions, to complete a full acquisition of those assets and bring them into the Virbac portfolio — something we have done with a number of our assets previously and something that is, again, genuinely a core part of our business. These transactions are smaller in scale than something like Thyronorm, which we discussed at the end of last year. That said, it's not the case that our team isn't extremely active and continuing to chase other bolt-on acquisition opportunities, since again, that remains a core and critical element of our growth model, complementing the strong organic growth we always aim for. With that, I'll hand over to Habib for a bit more flavor and detail on some of the financial performance. And of course, we'll be here for Q&A later.
Habib Ramdani
executiveThanks, Paul. Good morning, good afternoon, and good evening, everyone. I'm glad to be here today to walk you through our financial results — the half-year figures as of the end of June 2026. Let me begin with the customary key takeaways from our financials. As Paul mentioned, top line development has been very solid. At the end of June we reached EUR 768 million, representing 7.4% growth at constant exchange rate and scope. I'm especially pleased that this is a qualitative performance, with a good balance of volume and price. It comprises a 5% volume increase, very dynamic, plus a disciplined 2% price increase. It's also extremely qualitative geographically. I won't repeat what Paul shared, but you've seen that all three regions contributed significantly to sales development. Lastly, we can also note Thyronorm's contribution to those results at the end of June. During the semester, Thyronorm added 1.4 points of growth. It's also particularly solid on EBIT adjusted. We closed the semester with EUR 144.2 million of EBIT margin, a ratio to revenue of 18.8%.
Habib Ramdani
executiveAnd the net result came in at EUR 87.1 million, representing a 6% rise compared with the first semester of 2025. I'll get the chance to walk through more of the specifics during the presentation. Turning to the other financial indicators, net cash flow generation was very solid too, at roughly EUR 130 million in the first semester, while CapEx spending kept climbing in line with what we expected, reaching EUR 57 million. As you can see, we closed the semester with net debt of EUR 200 million, a slight uptick from the end of December 2025, largely because of the usual seasonality we experience each year. And as you'll see later, we still anticipate cash generation of about EUR 80 million for the year 2026. Before we get into the segments, let me spend a few seconds on the exchange rate impact. As you can see, currency effects have created some headwinds for us. The top line took a negative hit of EUR 25 million, and our bottom line, EBIT adjusted, was negatively affected by around EUR 5 million.
Habib Ramdani
executiveBut the encouraging part is that during this semester, shifts in currency have not caused any movement in our ratio of adjusted EBIT to revenue, and that figure has held steady at 18.8%. So currency is having no effect on our EBITA ratio. Unlike a year ago, if you recall, currency movements diluted that ratio. I can add that more recently we are observing a much smaller impact. In fact, during August, currency had almost no effect on our top line. Of course, we have no crystal ball, so predicting how the year will end is difficult. Still, August at least brought an improved situation. Let me now turn to how net revenue evolved by segment. I will begin with the revenue split between companion animals and farm animals, which has stayed remarkably stable, and our portfolio remains very balanced, with 60% of revenue coming from companion animals and roughly 40% from farm animals. If we dig further into the companion animals product ranges and examine where growth originates, from a segment perspective, you can see three main segments whose growth rate came in near double digit or at double digit, with growth above double-digit rates.
Habib Ramdani
executiveStarting with specialty, that grew 23%. Clearly, part of this reflects Thyronorm being integrated, though certain other products—or product lines—from our Supercharge platform also added a fairly meaningful amount, among them the mobility ranges, Movoflex and URSOLYX, which Paul mentioned before. Pet food also delivered a strong semester, still expanding at a double-digit pace, near 14%. For the other segment, where our dental Supercharge categories are reported too, you'll notice growth of roughly 9%. Parasiticides are the sole segment declining in that semester, which lines up well with what we saw last year on our product portfolio. Yet, as you'll note, that is largely offset by really healthy momentum across the remaining segments. Turning to farm animals now: companion animal overall was up 10%. We also posted a very robust top line performance—top line expansion—in farm animals, at about 7% on a constant exchange rate and scope basis, so quite robust. There too, a handful of segments, three of them, are adding quite nicely to growth. Nutritionals comes first, with a 20% rise in our revenue there.
Habib Ramdani
executivePaul also brought up a few of those Supercharge categories with ITMS. And clearly, that's also been fueled by the extremely strong results we saw in India over that semester, consistent with what we've seen in recent years in that country. The vaccine side had a very robust semester too, with 8% growth. That's a combination of the Bluetongue vaccine in Europe and the reproduction vaccine in other regions, Latin America included. In the other segment, you can also see 17%, with reproduction and anti-inflammatory products contributing quite well. Conversely, parasiticides came down, mainly tied to the situation in Australia, where we're struggling and saw our sales fall during that semester. As you're aware, we shared that previously. And aquaculture too, with EUR 1 million less in revenue, essentially tied to one product whose distribution we lost. But all in all, once again, a very solid showing across our two legs, companion animal and farm animal. Let me now turn to the P&L statement to talk about our EBIT adjusted and net income. You'll see that our gross margin on material cost has risen as a percentage of revenue.
Habib Ramdani
executiveSo we went from 67.4% to 68.4%, and that comes from a favorable mix effect, thanks to our Supercharge product, which tends to carry a higher margin than the group average. We also get the benefit of Thyronorm, plus some base effect tied to a one-off we had last year, if you recall. Now, if you look at the combination of net expenses, depreciation, and provisions — all the other expenses in our P&L beyond raw materials and consumables used — you'll see that their ratio to revenue went up by 0.5 point, and the combination of a positive point on gross margin on material cost and a 0.5 point decrease let us raise our EBIT adjusted before amortization and acquisition by 0.5 point as well. So a very solid performance, moving from 18.3% to 18.8%. Let me say a bit about this rise in expenses as a ratio to revenue. It's essentially made up of two elements. One is a positive impact linked to R&D spending, and you can see some of that in external expenses, which rose by only 2%. So it's tied to limited R&D spending versus last semester, but it's essentially a phasing effect versus 2025.
Habib Ramdani
executiveWe anticipate that will return to normal over the course of 2026. Regarding operating expenses, before R&D, we see somewhat of that same phasing impact. But in the opposite direction, we incurred greater expenses during the first semester of 2026 compared with the first semester of 2025. Yet here too, this will return to normal for the full year 2026. And lastly, I should also note certain one-off expenses we had in that semester that also play a part in explaining the 1.3 point rise in our operating expense as a ratio to revenue. But this too, obviously, will -- as a ratio to revenue will come down when we look at the full year. So overall, we are, once again, reaching 19%. And the pattern of this first semester combined with what we expect for the rest of the year leaves us very comfortable and very positive about our ability to hit the guidance we have confirmed on EBIT adjusted, which is 17% as a ratio to revenue for the entire year. Let me now move down to the remainder of the P&L. You can see that the depreciation of intangible assets arising from acquisitions has risen. Comparing the first semester last year with the first semester of 2026, it has almost doubled.
Habib Ramdani
executiveSo essentially, this ties to how depreciation on assets from the Thyronorm acquisition is being integrated. During the first semester of 2026, we booked slightly above EUR 5 million in other nonrecurring income and expenses. A year earlier, there was nothing in that line. That EUR 5.6 million therefore comes down mainly to two items. The first involves depreciation of stock and equipment tied to the halt in commercialization of one of our products. The second relates to damages we incurred within one of our wholesalers. Those damages have been recorded, and we're currently working with our insurer to have them covered. Two last points on the remainder of the P&L. The first concerns financial income and expenses. As you can see, we improved there, going from EUR 8.5 million in expenses to EUR 3.2 million. That's mainly driven by exchange-rate effects. Last year we had some negative impact tied to how the CLP, the Chilean currency, moved, and that hit our semester, while this year the CLP has been more stable when you compare the end of December 2025 with the end of June 2026.
Habib Ramdani
executiveIncome tax has stayed pretty steady compared with last year. Its movement tracks the group's activity. Taken together, all of this lets us post a higher net income, rising from EUR 82 million to EUR 87 million. Now let me turn to free cash flow. As you can see, it comes in at minus EUR 7 million in H1 2026. That's a better position than last year. It also lines up very well with what we had anticipated for that first semester. The two main factors behind the -- our net free cash flow are, clearly, CapEx spending. As you can see, we spent EUR 57 million during the first semester. That's a bit above what we expensed last year. It relates to the industrial -- most of it relates to the industrial project transformation currently underway, with the 3 to 4 key projects that Paul mentioned earlier. On working capital, we had a requirement of EUR 80 million. Here, you probably recall that we typically see a seasonality effect, with requirements during the first part of the year on working capital, particularly tied to our commercial model and the end of year rebate that gets paid during the first part of the year, and the combination of CapEx and working capital requirement roughly equals our generation of net cash flow, which has gone up, by the way, by around 30% versus last year.
Habib Ramdani
executiveAlright, taking all of that into account, it clarifies how our net debt position has evolved. As you can see, we closed out last year, 2025, at roughly EUR 173 million. By the end of June, our net debt had risen modestly to EUR 196 million. Two points to make here. First, this is very much in line with what we had anticipated and with the seasonal patterns we typically experience in our first semester. Second, as the bottom text shows, our balance sheet remains in a very favorable position, and so does our leverage — with a net debt on EBITDA ratio of 0.6 as of the end of June 2026. I'll move very quickly through the consolidated balance sheet. You can see how our working capital evolved between December and June, though again, this ties back to seasonality. And you can see the healthy ratios we have — net debt on net cash flow and net debt on operating cash flow — rising slightly, but again, essentially due to seasonality. Let me say a few words about our shareholding structure. This will be very brief. Our majority ownership remains in place, with the Dick Family holding slightly more than 50% of the shares and 66% — slightly more than 66% of the voting rights.
Habib Ramdani
executiveThings are pretty much steady compared with where we stood last year — nothing has shifted on that front. And before we open it up to Q&A, I want to finish by walking you through our full year guidance for 2026, which is unchanged from what we laid out in July. We're still aiming for the top end of the original net revenue growth target we gave at the start of the year — 5.5% to 7.5% at constant rates and scope. For the full year 2026, we continue to expect an EBITDA margin and adjusted EBIT margin of roughly 17%. CapEx for the year will come to around EUR 125 million — approximately EUR 125 million — and all of that should let us bring in about EUR 80 million of cash, again at constant rates and scope, for 2026.
Carole Manducher
executiveThanks so much, Paul and Habib. I'd suggest we go ahead to the question now. And Taron, you'll take us through the various questions.
Taron Hovhannissyan
executiveSure. Actually, we can jump straight in — go ahead with the guidance. One thing people are asking: can you explain the reason you're forecasting a 17% EBIT margin, compared with 18.8% for the first half year?
Habib Ramdani
executiveYeah, I bring this up quite a lot, and each year we see a similar pattern of seasonality. Our adjusted EBIT margin usually comes in higher in the opening portion of the year than it does across the whole year. So that's been consistent. Looking back at what we've published historically over the last 5 years, the gap runs between 2 to 4 points, varying by year and by how certain investments are phased. We're sitting closer to the bottom end of that. This year the picture is more balanced than in some earlier years, but it's the usual seasonality we observe. Part of that ties to the budget cycle and to the fact that things tend to slip a little right at the start of the year.
Taron Hovhannissyan
executiveThe following question concerns depreciation and provisions. This individual has observed that our depreciation and provisions went down during the first half relative to last year. They also ask when the CapEx we are putting in will hit the DAP in the years ahead, or after?
Habib Ramdani
executiveYeah, so there has indeed been a modest decline, though that's really an accounting artifact. Some products provisioned earlier were scrapped, and when that happens we reverse the provision. That explains the drop you're seeing. At the same time, on the line right above — other expenses — you'll notice the opposite effect shows up. The net result is zero, yet one line carries a plus and the other a minus, which makes it look like depreciation is falling. Absent that item, roughly EUR 3.5 million, depreciation is in fact rising, and rising slightly. Most of the large transformation projects we've discussed haven't started affecting the numbers yet, since none of them have gone live. Their impact on depreciation will therefore appear in later years, once those projects go live. But clearly, we also anticipate some favorable effect that will offset part of that amortization through productivity.
Taron Hovhannissyan
executiveMoving on to Porus One and Vetcare — can you put a number on the revenue we're anticipating from those two products?
Paul Martingell
executiveOn that question, we don't reveal every detail. Still, it's fair to say these are plainly not on the same scale as Thyronorm, where we'd offer more color. These are really typical bolt-on commercial deals, though I think we could put them in the low double-digit million range, just to give a bit of color. More importantly, they add growth and margin from year 1. And in fact, if the acquisition gets triggered, that would enhance margin even further, since we would obviously eliminate the royalties at that stage. But yes, from '27 onward, growth and margin enhancing for Virbac Group.
Taron Hovhannissyan
executiveContinuing with M&A. The following question concerns North America. That's an area of focus for us. And the individual is asking whether this remains — whether we're still examining that region. Are there targets in that market? And what type of targets are we considering in terms of products, technology, industrial capacity?
Paul Martingell
executiveAs I mentioned, we remain extremely active on the M&A front. I think it's worth noting that we aren't seeing any slowdown when it comes to opportunities on the table. Our team stays consistently mobilized and very active. Over the past years, we've built a very strong capability in M&A and licensing as a core part of our strategy. So you can trust that we continue to look and, of course, be strategic on one side, seeking the right deals, with the U.S. as a focus. And yes, of course, we would like to add significantly more scale in the U.S. So that's absolutely priority #1 in terms of focus for the M&A team. But of course, we also remain agile so we can be ready for what's available. And of course, you know that we have to adapt to both. So we are both very active. We'll continue to be disciplined, but plenty of ongoing conversations are happening.
Taron Hovhannissyan
executiveThank you. The next question concerns energy prices in light of the international crisis. Would you expand on that subject, please?
Habib Ramdani
executiveYeah. Clearly this is a subject — more broadly, how inflation is moving on certain of the components, raw materials, and products we purchase, energy included, obviously. We don't — we're handling that quite actively. In some of our countries, France among them, where a solid share of our energy consumption sits, we've put hedges in place. So for the next 2 years we aren't really exposed, either on electricity or on gas, thanks to a fixed price that has been arranged. And we're managing actively by means of negotiation. And we've shared that no material impact is expected in 2026 from the inflation, including the inflation on energy.
Taron Hovhannissyan
executiveOne more question, this one on the financial side, regarding inventory and working capital. Should we expect, over the coming years, to return to normal levels for both inventory and working capital?
Habib Ramdani
executiveOn inventory, what we've said is that following COVID and the beginning of the war in Ukraine, our inventory went up. We wanted to be certain we had everything needed to serve demand and our customers. So we raised inventory wherever it was necessary and required. Since then, we've worked to optimize, and inventory as a ratio to revenue has come down. We hit a very high point 2.5 years ago. Since then, it has declined. We'll keep optimizing wherever possible. At a specific moment, we can see a one-off increase. For example, in one of our projects, production is being transferred from one site to another. When that happens, obviously, you want to be sure you won't hit a shortage, so you can temporarily raise inventory. So we may see slight up and down movements tied to that. But the trajectory should keep declining. It won't be a material decrease over the coming years, but more of an optimization wherever we can.
Taron Hovhannissyan
executiveIf we circle back to the M&A questions on Thyronorm, could you share a bit more color on the market share position we hold for that product? And what catalysts lie ahead, or anything on the sales, commercial, and marketing side that we can leverage and provide?
Paul Martingell
executiveOkay, so to start off, I'm glad to report that the integration has gone remarkably well, from the standpoint of both the brand and the business team. And as you can tell from some of the figures we've shared today, we're actually running somewhat ahead of what we had anticipated earlier. If you recall, one thing that's fairly distinctive regarding the Thyronorm deal is that, to some degree, it's a deal structured in phases. So additional geographies will come under direct Virbac ownership and management in the years ahead, and that includes most of Europe, which is happening now in 2027. So the rollout and the effect of Thyronorm, let's say, isn't a one-time event. It's something that's going to unfold across a number of years. And yes, in '27, Europe is the big piece coming. At the same time, now that this asset sits with us, we'll of course keep investing in the science, in the post-launch studies, and in the brand building that's needed to keep growing that asset as a core element of our portfolio. So that's certainly an asset we think still has more runway for growth, and also, once again, the complementarity with other areas of our portfolio delivers additional benefits there as well.
Taron Hovhannissyan
executiveStill on M&A — the question is about which metrics we look at when assessing a deal. And for valuation, is it EBITDA multiples — adjusted EBIT multiples for larger deals? And what else do we use on smaller deals?
Habib Ramdani
executiveRight, so several different factors are at play here. Obviously, we run the classical NPV analysis. We examine the return on investment. And what matters a great deal to us is the effect on the rest of the group. From a qualitative angle, we want to be sure it adds nicely to product country, but also that its relative impact on the bottom line and the top line is positive — those are the preferred deal; plus synergies creation on the top line as well, across the rest of the portfolio, when you have positive synergies on product ranges and on cost synergies too, which are included in our model.
Taron Hovhannissyan
executiveMoving on to the next question, which concerns CapEx — could you revisit the CapEx roadmap for our industrial segment?
Habib Ramdani
executiveYes. So we said there's a very intense industrial transformation underway, with several major CapEx investment projects aimed at preparing for the future — creating additional capacity, renovating some of our existing sites, and also internalizing certain production that involves strategic products for us, in ranges like pet food. That's what's driving this industrial transformation of ours. It will also let us raise our productivity as we go through it, obviously. We've said we expect to be above EUR 100 million for a few years. Beyond that, obviously, it's quite difficult. We don't necessarily have full visibility, right? This is a very significant transformation that's ongoing.
Taron Hovhannissyan
executiveTo revisit CapEx, once that acceleration has run its course, what proportion of revenue would be a sensible level for CapEx in the 2 or 3 years that follow this ramp?
Habib Ramdani
executiveAs I just said, anticipating this is rather hard. As the top line rises, we should see that ratio to revenue come down, and some of those large projects will be behind us. Still, what we do know is that for a few years we'll be above EUR 100 million. Beyond that, it's too soon to say. What I can say is that cash generation matters a great deal to us. Our focus on producing cash is very, very strong. We want to keep being able to activate external growth. And we know that requires very healthy and solid cash generation.
Taron Hovhannissyan
executiveThere's a question about one-off costs. Can you break down what made up that one-off cost we had in H1? And does it tie to things like litigation settlements, product discontinuation, and so on?
Habib Ramdani
executiveRight, so basically it comes down to discontinuing certain products. As we trimmed the portfolio, a handful of smaller items were phased out, and that set off some costs — one-time charges plus a few litigation settlements. So when you get a few million euros of that landing in a single semester, it shows up somewhat. Those one-off costs amount to 0.3 to 0.4 points of profitability impact for this semester.
Taron Hovhannissyan
executiveRegarding the Supercharge portfolio — does that portfolio exhibit the same seasonal patterns as the other products do?
Paul Martingell
executiveBroadly speaking, that piece remains fairly spread out across our business, correct? You've got 8 Supercharge platforms spanning both companion and farm; a few are quite nonseasonal, like mobility and dental, while others involving farm animals can be somewhat more seasonal, naturally. Still, all in all, Supercharge platforms see no significant seasonal effect. This is a segment that ought to stay fairly steady.
Taron Hovhannissyan
executiveThanks. I have two related questions. Which launches would be the big ones in the coming year? And what more could you share with us regarding the R&D pipeline?
Habib Ramdani
executiveOn product launches, we’re not in a position to say much. It’s too soon for that. We’ll address it at the point when we speak about 2027.
Taron Hovhannissyan
executiveMoving on, the next question concerns the potential fertility campaign in Australia. Perhaps we need a bit more — I believe it was Delphine. Delphine, maybe you could offer further feedback or add more detail on that question. I'll move to the following question. To hit the full-year margin guidance, you need H1 margins to improve by 150 basis points, compared with 50 basis points in H1. Kindly walk us through the building blocks behind that.
Habib Ramdani
executiveRight. It's basically how our spending is phased, and that's what will get us to 17% for the full year. As I said, some one-off items hit the first semester. We don't anticipate those in the second semester. So on a like-for-like basis, we're above 0.5. But really, it comes down to how our spending is phased between H1 and H2.
Taron Hovhannissyan
executiveI think that was the final question we had. One more has just come in. With the stock's valuation where it is, is a share buyback something you're looking at right now?
Habib Ramdani
executiveNo. For us, the real priority is making sure we have the means to keep considering external growth. So we genuinely favor external growth over other kinds of capital allocation, like share buybacks.
Taron Hovhannissyan
executiveLaurent is asking about the impact on the H1 EBIT margin.
Habib Ramdani
executiveRight, we haven’t broken that out to that level. For the full year, we expect 0.5 point. That’s probably about right — yes, likely roughly that for the first semester, though we haven’t gone into that level of detail.
Taron Hovhannissyan
executiveWhat's causing the OpEx phasing to look different in this year?
Habib Ramdani
executiveThe truth is, that figure shifts annually. It ties back to which kinds of projects we're looking at putting into place and the timing of when those get done. Where R&D is concerned, it hinges on how your clinical trials are staged and when you bring in some of the animals. So having that kind of variation is pretty normal, and we observe it each year.
Taron Hovhannissyan
executiveI notice Frederic is perhaps beginning...
Paul Martingell
executiveTo build on what was said regarding how OpEx is phased, I want to remind everyone again that our focus is on sustainable growth over the mid and long term. If our goal were simply to keep the profit figure where it stands, we could restrain things in the second half, but we intend to keep investing through the second half of the year so that we head into '27 and beyond, of course, with strong momentum. So this also reflects how we consistently invest for the long term.
Taron Hovhannissyan
executivePossibly this is the final question. Based on what number of deals might be up for grabs and how large they are, at what level would you feel comfortable with leverage?
Habib Ramdani
executiveYes. We've said before that up to 2 is absolutely no problem. We would definitely go there. We can even go above that, to 2.5. Going above 3 will require a very solid — we cannot rule it out, obviously, if we have a very strategic deal that makes a lot of sense and where we are confident that we can deleverage then with the right pace, we could consider. But definitely around 2, we would be very, very comfortable.
Taron Hovhannissyan
executiveThanks. That wraps up the Q&A. If anything else comes up, don’t hesitate to get in touch.
Paul Martingell
executiveThanks to all of you, and many thanks indeed.
Habib Ramdani
executiveAppreciate it.
Carole Manducher
executiveThanks so much.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Virbac SA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Virbac SA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Virbac SA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.